Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 18/20 | 0.59 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | PPARD | Q03181 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1878109 | 0.99 | IGF1R (0.60) | IGF1REPHX1EPHX2 | |
| SCHEMBL1884081 | 0.98 | IGF1R (0.57) | IGF1REPHX1EPHX2PPARGPPARD | |
| SCHEMBL1879433 | 0.97 | IGF1R (0.57) | IGF1RPPARGPPARDPPARA | |
| SCHEMBL4116738 | 0.87 | IGF1R (0.79) | IGF1R | |
| SCHEMBL31573112 | 0.87 | IGF1R (0.76) | IGF1RPPARGPPARDPPARA | |
| SCHEMBL4105626 | 0.87 | IGF1R (0.80) | IGF1R | |
| SCHEMBL4109719 | 0.86 | IGF1R (0.76) | IGF1RPPARGPPARDPPARA | |
| SCHEMBL1882989 | 0.85 | IGF1R (0.55) | IGF1RPPARGPPARDPPARA | |
| SCHEMBL4152463 | 0.85 | IGF1R (0.64) | IGF1RPPARGPPARDPPARA | |
| SCHEMBL1874688 | 0.85 | IGF1R (0.74) | IGF1RPPARGPPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1979339-B1 | NOVEL CYCLIC UREA DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS | AVENTIS PHARMA SA (FR) | 2012-10-31 | — | — | EP | disclosed |
| US-7935819-B2 | Cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors | AVENTIS PHARMA S.A. (FR) | 2011-05-03 | — | — | US | disclosed |
| US-7935819-B2 | Cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors | AVENTIS PHARMA S.A. (FR) | 2011-05-03 | — | — | US | disclosed |
| US-7935819-B2 | Cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors | AVENTIS PHARMA S.A. (FR) | 2011-05-03 | — | — | US | disclosed |
| US-20090082379-A1 | Novel Cyclic Urea Derivatives, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors | AVENTIS PHARMA S.A. (FR) | 2009-03-26 | — | — | US | disclosed |
| US-20090082379-A1 | Novel Cyclic Urea Derivatives, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors | AVENTIS PHARMA S.A. (FR) | 2009-03-26 | — | — | US | disclosed |
| US-20090082379-A1 | Novel Cyclic Urea Derivatives, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors | AVENTIS PHARMA S.A. (FR) | 2009-03-26 | — | — | US | disclosed |
| WO-2007083017-A2 | NOVEL CYCLIC UREA DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS | AVENTIS PHARMA S.A. (FR) | 2007-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082379-A1 | Novel Cyclic Urea Derivatives, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors | PRKAR2B, CDK1, PRKX | IGF1R 962/4885EPHX1 819/4885EPHX2 1155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.